Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Physicians who Treat Gestational Diabetes(?)

Council Members in this Study Group: 13

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

What is a GLG Leader?
RoseMarie Pasmantier, MD
Director, Diabetes Outpatient Department
SUNY Downstate Medical Center - CC

RoseMarie Pasmantier, MD, is Director of the Diabetes Outpatient Department at State University of New York at Stony Brook. Dr. Pasmantier has experience in the treatment of all metabolic disorders. Her research interests include new treatments for type II diabetes and dyslipidemia. Dr. Pasmantier has...


Joseph Bass, MD, PhD
Division Head of Endocrinology and Metabolism
Evanston Northwestern Healthcare

Joseph Bass, MD, PhD, is Assistant Professor of Medicine and Neurobiology at Northwestern University in Illinois and Division Head of Endocrinology and Metabolism at Evanston Northwestern Healthcare. He is also the Director of a federally-funded basic research program on obesity, diabetes, and lipid...


4 recent news post(s)

Related Study Groups

GLG NewsSMAnalyses by this Study Group's Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Another Glinide: Where's the Beef? | 03-28-2008
Analysis of: Elixir Announces Completion of Enrollment in Pivotal Phase III Clinical Trial for New Diabetes Drug | www.pipelinereview.com
Author: Joseph Bass, MD, PhD, Division Head of Endocrinology and Metabolism, Evanston Northwestern Healthcare

Elixir has turned to a strategy devoid of innovation by selecting a combination glinide (metiglinide) plus glucophage for treatment of type 2 diabetes.  With the new availability of DPP4 inhibitors (sitagliptin/alogliptin) and incretin agonists (eg byetta), what is the prospect of another K channel...

Warning on A1C Targets and Diabetes Death in ACCORD Trial | 02-08-2008
Analysis of: Hault of ACCORD Study Intensive Treatment Arm | www.nhlbi.nih.gov
Author: Joseph Bass, MD, PhD, Division Head of Endocrinology and Metabolism, Evanston Northwestern Healthcare

Increased death from intensive A1C lowering in diabetic subjects raises new concerns about diabetes therapy, insulin use in combination with oral agents, and clinical biomarkers of disease complications.

Predicting Winners in Oral Diabetes Competition: Galvus, Alogliptin & Januvia | 02-05-2008
Analysis of: Galvus(R), A New Treatment For Patients With Type 2 Diabetes, Receives European Approval For Label Update Paving The Way For EU Launches | www.pipelinereview.com
Author: Joseph Bass, MD, PhD, Division Head of Endocrinology and Metabolism, Evanston Northwestern Healthcare

Oral therapies improve complianceEU approval of Galvus does not erase US doubts

Alogliptin on the diabetes horizon. | 01-09-2008
Analysis of: Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S. | www.pipelinereview.com
Author: Joseph Bass, MD, PhD, Division Head of Endocrinology and Metabolism, Evanston Northwestern Healthcare

Diabetes is on the rise globallyExisting oral therapeutics have significant drawbacks but are cheap (generic) and some have been in use for many years.

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic
  • Private/For-Profit Healthcare Research Entity
  • Research Foundation

Most Common Job Types:

  • Physician - Attending Physician
  • Owner
  • Physician - Division Head
  • Medical Director
  • President
  • Director
  • Partner
  • Physician - Director

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics